2022
Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy
Harold JA, Casilla-Lennon M, Kenney PA, Ratner ES. Vesical clear cell adenocarcinoma of Müllerian origin treated conservatively with partial cystectomy. BMJ Case Reports 2022, 15: e245015. PMID: 35383096, PMCID: PMC8984011, DOI: 10.1136/bcr-2021-245015.Peer-Reviewed Original ResearchConceptsClear cell adenocarcinomaPartial cystectomyCell adenocarcinomaMüllerian originPAX-8 stainingExtensive endometriosisAdjuvant therapyFinal pathologyTotal hysterectomyTransurethral resectionBladder massResidual tumorCystectomyAdenocarcinomaHysterectomyEndometriosisResectionTherapyTumorsPathologyWomen
2020
Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma
Hsiang WR, Kenney PA, Leapman MS. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma. Current Oncology Reports 2020, 22: 35. PMID: 32170461, DOI: 10.1007/s11912-020-0895-y.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaSystemic therapyRenal cell carcinomaCytoreductive nephrectomySurgical therapyCell carcinomaManagement of mRCCPoor-risk metastatic renal cell carcinomaInitial systemic therapyReviewThe treatment landscapeTargeted therapy eraUpfront cytoreductive nephrectomyViable treatment approachSequence of surgeryTherapy eraTreatment landscapeUnselected patientsSurgical managementSummaryRecent evidenceRecent FindingsOneTreatment approachesNephrectomyTherapyOptimal rolePatients
2019
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Abello A, Kenney P. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2019, 411-435. DOI: 10.1007/978-3-030-24378-4_24.Peer-Reviewed Original ResearchRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaDisease-free survivalHigh-risk subsetVenous tumor thrombusTyrosine kinase inhibitorsAdjuvant settingCytoreductive nephrectomyUnresectable diseaseAdjuvant therapyAdvanced diseaseNeoadjuvant therapyOverall survivalTumor thrombusGenitourinary malignanciesPartial nephrectomySignificant causeTherapyEffective agentNephrectomyMonoclonal antibodiesKinase inhibitorsDisease
2013
Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney P, Wood C. Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma. 2013, 155-177. DOI: 10.1007/978-1-4614-7236-0_10.Peer-Reviewed Original ResearchSystemic therapyBenefit of cytoreductionTargeted therapy eraVenous tumor thrombusRenal cell carcinomaTyrosine kinase inhibitorsAdjuvant settingUnresectable diseaseAdvanced diseaseCytoreductive surgeryNeoadjuvant therapyTherapy eraAdjuvant therapyMetastatic RCCTumor thrombusGenitourinary malignanciesCell carcinomaPartial nephrectomySurgeryTherapyEffective agentMonoclonal antibodiesKinase inhibitorsDiseaseCurrent role
2012
Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma
Kenney PA, Wood CG. Integration of Surgery and Systemic Therapy for Renal Cell Carcinoma. Urologic Clinics Of North America 2012, 39: 211-231. PMID: 22487764, DOI: 10.1016/j.ucl.2012.01.005.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Agents, HormonalCarcinoma, Renal CellChemotherapy, AdjuvantCombined Modality TherapyFemaleHumansImmunotherapyKidney NeoplasmsMaleNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm StagingNephrectomyPrognosisRadiotherapy, AdjuvantRisk AssessmentSurvival AnalysisTreatment OutcomeConceptsRenal cell carcinomaSystemic therapyCell carcinomaMetastatic renal cell carcinomaAdvanced nonmetastatic diseaseUpfront cytoreductive nephrectomyIntegration of surgeryCytoreductive nephrectomyCytoreductive surgeryNeoadjuvant therapyNonmetastatic diseaseAdjuvant therapyMetastatic diseaseAppropriate patientsTherapySurgeryDiseaseCurrent roleNephrectomyFurther studiesCarcinomaPotential benefitsPatientsTrials